Press Releases

Back to previous page

ReGen Biologics Appoints Abhi Acharya, Ph.D. to Board of Directors

Franklin Lakes, NJ – May 19, 2003 – ReGen Biologics, Inc. (OTC: RGBI), an orthopaedic company specializing in the treatment of knee injuries, today announced that Abhi Acharya, Ph.D. has been named to the company’'s Board of Directors. Dr. Acharya, who has 30 years experience in the scientific, clinical, and business aspects of bringing medical devices to market, including 16 years at the Food and Drug Administration (FDA), will be instrumental in supporting ReGen's clinical marketing and product development strategies.

"Dr. Acharya brings a broad range of expertise to our Board of Directors," stated Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO of ReGen. "His knowledge of U.S. and international device laws and regulations, clinical trial design and interpretation, product development processes, and regulatory and clinical marketing strategies will prove invaluable, especially as ReGen nears FDA product approval in the U.S."

Most recently, Dr. Acharya served as Senior Vice President, Regulatory Affairs, Quality, Clinical Research of EndoTex Interventional Systems. Throughout his distinguished career he has held several pivotal positions including Vice President, Regulatory Affairs, Quality Assurance and Clinical Research of Target Therapeutics, Inc. and Senior Technical Advisor at Biometric Research Institute, Inc. Dr. Acharya served at the Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration from 1977 to 1993 holding a variety of positions including Director, Division of Cardiovascular, Respiratory and Neurological Devices, Chief of Surgical Devices Branch, and Chief, Engineering and Physical Science Branch, Division of Ophthalmic, Ear Nose Throat and Dental Devices. At the FDA, he participated in regulatory and scientific policy formulation at the highest levels of that organization and with oversight committees of the US Congress.

"I am pleased to have this opportunity to contribute to ReGen's leading role in the advancement of products to restore patient mobility," stated Abhi Acharya, Ph.D. "“I look forward to working with ReGen to advance the CMI and other offerings in the U.S. and abroad."

Author of numerous publications and a frequent speaker at medical, regulatory and policy meetings, Dr. Acharya has received the FDA Award of Merit, the Commendable Service Award, the Commissioner's Special Citation and was a member of the Senior Executive Service of the United States. He earned his M.S. and Ph.D. in Biomedical Engineering from Northwestern University and a B.S. in Metallurgical Engineering from the Indian Institute of Technology.

About ReGen Biologics, Inc.
ReGen is a tissue remodeling company that develops products that restore injured tissue. When applied to orthopaedics, ReGen’'s patented core technology has resulted in the CMI, which uses the body's own healing process to grow healthy new meniscus tissue and restore mobility for patients with certain knee injuries. ReGen has recently completed enrollment in its U.S. Multicenter Clinical Trial of the CMI. The CMI is currently distributed in Europe, Australia, Chile and certain other countries through Centerpulse (NYSE: CEP) and it is expected to be selectively available in Canada during 2003.

For more information on ReGen’'s next generation tissue regeneration products, visit www.regenbio.com, call 201-651-5140, or email info@regenbio.com.

Contact:
Katrina Pruitt-Andrews
KPA Marketing & Public Relations
301-604-7377 direct; 301-704-4087 cell
Kpandrews@comcast.net


Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the managements of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's annual report on Form 10-K/A, filed with the Securities and Exchange Commission for the year ended December 31, 2002. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services, and at the Web site maintained by the SEC at http://www.sec.gov.